论文部分内容阅读
目的观察重组人p53腺病毒注射液联合顺铂治疗肺癌所致心包积液的临床疗效。方法将84例诊断为肺癌晚期所致心包积液的患者分为观察组和对照组,各42例,患者在采用一次性中心静脉导管行心包积液引流后,对照组给予顺铂注射液40mg/m2心包内注射,每周重复1次,连续使用4周;观察组给予重组人p53腺病毒注射液1×1012 VP联合顺铂注射液40mg/m2心包内注射,每周重复1次,连续使用4周。比较治疗后二组患者治疗心包积液疗效、生活质量改善情况及不良反应等。结果观察组有效率高于对照组,患者生活质量改善情况明显优于对照组,差异具统计学意义(P<0.05)。观察组除发热例数多于对照组(P<0.05),其余不良反应二组差异无统计学意义(P>0.05)。结论重组人p53腺病毒注射液联合顺铂治疗肺癌心包积液疗效确定,有效改善患者生活质量,安全可靠,是一种有效的治疗手段,值得临床推广应用。
Objective To observe the clinical efficacy of recombinant human adenovirus p53 combined with cisplatin in the treatment of pericardial effusion induced by lung cancer. Methods Eighty-four patients diagnosed as pericardial effusion caused by advanced lung cancer were divided into observation group and control group, with 42 cases in each. After drainage with pericardial effusion by disposable central venous catheter, the control group was given cisplatin injection 40mg / m2 pericardial injection, repeated once a week, continuous use for 4 weeks; the observation group given recombinant human adenovirus p53 injection of 1 × 1012 VP cisplatin injection 40mg / m2 pericardial injection, repeated once a week, continuous Use for 4 weeks. Comparison of two groups of patients after treatment of pericardial effusion efficacy, quality of life improvement and adverse reactions. Results The effective rate of the observation group was higher than that of the control group. The quality of life of the observation group was better than that of the control group (P <0.05). In the observation group, the number of fever was more than that of the control group (P <0.05), and there was no significant difference in the other two groups (P> 0.05). Conclusion Recombinant human p53 adenovirus injection combined with cisplatin in the treatment of lung cancer pericardial effusion to determine the efficacy and effectively improve the quality of life of patients, safe and reliable, is an effective treatment and is worthy of clinical application.